INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")
Novo Nordisk agrees to acquire IBT portfolio company Akero
IBT notes the announcement this morning that Akero Therapeutics, Inc. ("Akero") has entered into a definitive agreement to be acquired by Novo Nordisk for up to $5.2 billion in cash.
Based in San Francisco, Akero is a clinical-stage biotech company focused on metabolic diseases. Addressing an area of high unmet medical need, efruxifermin ("EFX"), its flagship treatment for metabolic dysfunction-associated steatohepatitis (MASH), is in late-stage development.
Under the terms of the agreement, Akero shareholders will receive $54.00 per share in cash at closing and a non-transferable Contingent Value Right entitling holders to receive a cash payment of $6.00 per share upon full US regulatory approval of EFX for treatment of compensated cirrhosis due to MASH, by 30 June, 2031.
This agreed offer represents a 19% premium to Akero's 30-day Volume Weighted Average Price (VWAP), and a 42% premium to Akero's closing price on 19 May 2025, prior to market speculation. As at close of business yesterday, 8 October, Akero represented 2.9% of IBT's Net Asset Value, as included in IBT's regular daily NAV update earlier this morning.
Commenting on the news, Ailsa Craig and Marek Poszepczynski, portfolio managers of IBT, said:
"Novo Nordisk's acquisition of Akero is IBT's 8th M&A deal for a holding in our portfolio so far this year, and our 33rd since 2020, with our investment strategy focused on identifying potential acquisition targets continuing to deliver returns for shareholders. Large pharmaceutical companies face challenging patent expiries over the coming years, driving continued appetite for acquisitions of biotech companies. We therefore expect this strong period of M&A activity to persist for the foreseeable future, creating further opportunities for IBT to take advantage."
The updated valuation of IBT's holding in Akero will be included in IBT's NAV as at close of business today, to be reported in the usual way tomorrow morning, 10 October.
To sign up for IBT updates by email, please click here.
ENDS
Enquiries:
| Schroder Investment Management Limited Kirsty Preston (PR) Natalia de Sousa (Company Secretary)
|
020 7658 6000 020 7658 6000
|
| Kaso Legg Communications (Financial PR) Charles Gorman Henry Taylor Effie Aye Maung Hider |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.